Serum interleukin‐6 predicts the development of multiple symptoms at nadir of allogeneic hematopoietic stem cell transplantation

Abstract

These results suggest that release of systemic inflammatory cytokines, mainly IL-6, corresponds to an increase in treatment-related multiple-symptom burden during the nadir period of allo-HSCT.